SQUAWK/NEWS
Menu
Live News EQUITY FLASH H impact

Curis Doses First Patients in TakeAim CLL Study

Curis starts dosing in TakeAim CLL study

CRIS

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.